Listed

RenovoRx, Inc.: Form 10-K for the period ended Dec 31, 2022

Filed with the SEC on Mar 31, 2023 and accepted by EDGAR at Mar 31, 2023, 16:31 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2022-01-01 to 2022-12-31$4.3mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2022-01-01 to 2022-12-31−$9.9mus-gaap:OperatingIncomeLoss
Net income12 months2022-01-01 to 2022-12-31−$9.9mus-gaap:NetIncomeLoss
Basic EPS12 months2022-01-01 to 2022-12-31−$1.09us-gaap:EarningsPerShareBasic
Operating cash flow12 months2022-01-01 to 2022-12-31−$8.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2022-12-31$4.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-12-31$7.3mus-gaap:AssetsCurrent
Total assetsAt period end2022-12-31$7.3mus-gaap:Assets
Total liabilitiesAt period end2022-12-31$1.1mus-gaap:Liabilities
Shareholders' equityAt period end2022-12-31$6.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-23-010332. Last ingested by Listed: Nov 6, 2026, 17:30 ET. Listed shows no prices and gives no investment advice.